Arcus Biosciences, Inc. (NYSE: RCUS)
Health Care · Biotechnology · US
$24.53
+0.49% today · +67.2% 1Y
Arcus Biosciences, Inc. (NYSE: RCUS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $3.11B and employs 601 people.
Over the last twelve months the share price has gained 67.2%, trading between 14.18 and 31.74.
Tweenvest scores Arcus Biosciences, Inc. across four factors: quality 39/100, value 46/100, growth 45/100. Its strongest factor is value.
RCUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.11B
- Revenue (TTM)
- $117.00M
- P/E
- —
- EPS
- -3.86
- Dividend yield
- —
- Beta (5Y)
- 0.94
- 52-week high
- $31.74
- 52-week low
- $14.18
- Avg volume (3M)
- —
- Shares outstanding
- 127.33M
- Employees
- 601
- Next earnings
- —
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
- ISIN
- US03969F1093
- Founded
- 2015
- Listed since
- Mar 14, 2018
- Exchange
- New York Stock Exchange
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Viking Therapeutics, Inc.NasdaqCM: VKTX | $3.33B | $28.43 | -0.28% |
| Celcuity Inc.NasdaqCM: CELC | $3.32B | $65.81 | -3.14% |
| CareDx, Inc.NasdaqGM: CDNA | $3.29B | $61.73 | -3.05% |
| Denali Therapeutics Inc.NasdaqGS: DNLI | $3.11B | $19.09 | -1.85% |
| Dyne Therapeutics, Inc.NasdaqGS: DYN | $3.11B | $16.15 | -2.94% |
| Acrobiosystems Co.,Ltd.SZSE: 301080 | $3.06B | CN¥122.20 | -13.38% |
| Xiamen Amoytop Biotech Co., Ltd.SHSE: 688278 | $3.01B | CN¥50.77 | -4.01% |
| Keymed Biosciences Inc.SEHK: 2162 | $2.94B | HK$78.30 | -0.70% |
Figures last refreshed Oct 11, 2026.